At Penn State, scientists have peered into the molecular architecture of BRD4—a protein long entangled with cancer—and found that its grip on chromosomes is more versatile, and more surprising, than the field had assumed. Using cryo-electron microscopy to resolve structures at near-atomic scale, the researchers discovered that BRD4 can anchor itself to genetic material through multiple pathways, including one that requires no chemical signal at all. This challenges a foundational assumption that had guided drug development for years, and quietly expands the map of where and how this protein op
3D structure reveals how cancer-linked BRD4 protein binds chromosomes
A protein that binds without the signal everyone thought it needed
Mark
So they found that BRD4 can bind to chromosomes without a chemical signal that everyone thought was required. Why does that matter?
Mimi
Because it means the protein has more ways to attach itself to DNA than we understood. If there are multiple pathways, then blocking one pathway might not be enough to stop it in cancer cells.
Luke
But they haven't shown this actually happens in living cells yet, right? The experiments were in vitro.
Mimi
Correct. They tested it in a controlled lab setting. Whether it happens inside a cell is still an open question.
Mark
What's the immediate practical application here?
Mimi
Right now, there isn't one. This is foundational knowledge. But if researchers can understand all the ways BRD4 binds to DNA, they can design drugs that target multiple pathways at once.
Luke
And the cryo-EM imaging—that's the real technical achievement here. They could see the whole nucleosome structure, not just a fragment.
Mimi
Exactly. Seeing the full context revealed interactions that studying isolated pieces never would have shown.
Mark
How surprised were the researchers by the unmodified histone binding?
Mimi
Very. One of the authors called it a total surprise. It contradicted what the field had accepted as settled science.
Luke
Which is worth noting—this is one team's finding. It will need to be replicated and tested in cellular systems before it reshapes the field's understanding.
Mimi
Fair point. But that's how science works. This is the beginning of a conversation, not the end of one.
The Pulse
- For decades, a chemical tag called acetylation was considered the essential key that allowed BRD4 to bind to chromosomes—new data shows that key may not be necessary at all.
- BRD4 was found to grip not just modified histone proteins but also raw DNA itself, revealing a protein with far more binding strategies than anyone had documented.
- When one of BRD4's bromodomains locks onto a histone, the protein reshapes itself into a platform that recruits other proteins—suggesting it functions less like a switch and more like a coordination hub.
- The discovery that BRD4 binds unmodified histones with nearly equal strength to modified ones sent the research team back to first principles, forcing a reassessment of what counts as established fact in chromatin biology.
- Researchers caution that whether this unmodified binding occurs inside living cells remains unknown, but if it does, entire categories of BRD4 activity in cancer may have gone unrecognized.
- The structural findings open new therapeutic angles—targeting BRD4's direct DNA contact or its unmodified histone grip, not just the acetylation pathway that current drug strategies have focused on.
At Penn State, scientists have peered into the molecular architecture of BRD4—a protein long entangled with cancer—and found that its grip on chromosomes is more versatile, and more surprising, than the field had assumed. Using cryo-electron microscopy to resolve structures at near-atomic scale, the researchers discovered that BRD4 can anchor itself to genetic material through multiple pathways, including one that requires no chemical signal at all. This challenges a foundational assumption that had guided drug development for years, and quietly expands the map of where and how this protein operates within the living cell.
Scientists at Penn State have mapped the three-dimensional structure of BRD4, a protein deeply implicated in cancer, and found that it attaches to chromosomes in ways that contradict decades of established thinking. The work, published in Molecular Cell and conducted using cryo-electron microscopy, resolves biological structures at near-atomic detail and reveals a protein far more flexible in its behavior than the field had recognized.
BRD4 belongs to a family of proteins that govern which genes cells activate, making it central to how DNA is read, copied, and repaired. It has been linked to numerous cancers and is already a target for drug development. The prevailing model held that BRD4 could only bind to nucleosomes—the repeating units that package DNA—when the histone proteins within them carried specific acetyl chemical tags. That tag was considered the necessary signal, the molecular key.
When lead researcher Song Tan's team imaged BRD4 bound to a complete nucleosome rather than isolated histone fragments, they found something the partial models had missed: BRD4 also binds directly to the DNA itself. They also observed that when a bromodomain locks onto a modified histone, BRD4 arranges into a platform that other proteins can dock onto—suggesting it acts as a coordination hub for multiple cellular processes at once.
The deeper surprise came in follow-up experiments. BRD4 bound to histones carrying no acetyl tags at all, and did so with nearly the same strength as it bound to modified ones. Co-first author Erik Leith described it as a total surprise—acetylation had been treated as dogma, and the new data showed it was not required. Whether this unmodified binding occurs inside living cells, where conditions are far more complex, remains an open question. But if it does, it could reveal biological roles for BRD4 that have never been recognized.
For cancer research, the implications are significant. The findings suggest there may be multiple ways to interfere with BRD4—not only by blocking the acetylation pathway, but by targeting its direct contact with DNA or its grip on unmodified histones. Tan noted that while the team's immediate focus was basic biology, these structural insights could eventually guide the development of more effective treatments for the cancers in which BRD4 plays a central role.
Scientists at Penn State have mapped the three-dimensional structure of BRD4, a protein long implicated in cancer development, revealing how it latches onto chromosomes in ways that contradict decades of established thinking in the field. The discovery, published in Molecular Cell, was made using cryo-electron microscopy—a technique that can resolve biological structures down to near-atomic detail—and it opens unexpected avenues for understanding how this protein works and, potentially, how to disrupt it therapeutically.
BRD4 belongs to a family of proteins that control which genes cells turn on and off, making it essential to how cells read, copy, and repair DNA. It has been linked to numerous cancers and is already considered a promising target for drug development. The protein uses structures called bromodomains to bind to chromosomes, specifically to the repeating DNA-packaging units called nucleosomes. Until now, the prevailing model held that BRD4 could only attach to nucleosomes when its bromodomains encountered histones—the proteins that package DNA—that had been chemically modified with acetyl tags. This modification was thought to be the necessary signal that allowed the interaction to happen.
Song Tan, who led the research team, explained that previous structural studies had examined BRD4 bound only to fragments of these modified histone proteins. The team wanted to see what would happen if they imaged BRD4 attached to an entire nucleosome in its full biological context. Using cryo-EM, they discovered that BRD4 did indeed bind to the modified histones as expected, but it also bound directly to the DNA itself within the nucleosome. The structure revealed something else: when one of BRD4's bromodomains binds to a modified histone, the protein arranges itself in a way that creates a platform for other proteins to interact with it—a finding that suggests BRD4 functions as a hub coordinating multiple cellular processes simultaneously.
The real surprise came next. The team ran additional experiments to test whether BRD4 could still bind to nucleosomes even without those chemical acetyl tags on the histones. It could. In fact, BRD4 bound to unmodified histones with nearly the same strength as it bound to modified ones. This finding directly contradicted what had been accepted as established fact in the field. Erik Leith, a recent doctoral graduate who was a co-first author of the paper, called it a total surprise. The acetylation tag had been considered dogma—the necessary key that unlocked BRD4's ability to recruit itself to nucleosomes. The new data showed that key regions of the BRD4 protein itself could bind to unmodified histones without any chemical signal at all.
The implications are still being worked out. Leith noted that the team does not yet know whether this unmodified histone binding actually occurs inside living cells, where the chemical environment is far more complex than in a test tube. But if it does happen in cells, it could reveal entirely new biological contexts where BRD4 and related bromodomain proteins play roles that have never been recognized. For cancer research and drug development, the finding matters because it suggests there may be multiple ways to interfere with BRD4's function—not just by blocking the acetylation signal, but by targeting the protein's direct interaction with DNA or unmodified histones. Tan emphasized that while the team's immediate focus was understanding the basic biology of how BRD4 works, these structural insights could eventually guide the development of more effective treatments for the cancers in which this protein plays a role.
Notable Quotes
We were motivated to understand the basic biology of BRD4 and what it can teach us about the structure and function of this group of proteins. While the role of BRD4 in cancer was not our immediate focus, as we continue to build a better understanding of its function, we hope to reveal clues that could be used in the development of more effective treatments.— Song Tan, Penn State
It was dogma in the field that the acetylation chemical tag on the histone was needed to recruit the bromodomain to nucleosomes, but our research shows that key regions of the BRD4 protein help it to bind to unmodified histones.— Erik M. Leith, Penn State doctoral graduate
Want the full story?
Read the original at News-Medical ↗
Science & Space